TAUNS Laboratories (197A) · RiskAdvanced
Decline in Product Superiority Due to R&D Delays and Competing Technologies
First written in FY2024. 1 of 2 entries say "Advanced", first in FY2026. Latest entry: FY2026.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Product Obsolescence Due to Intensified Competition and Delays in Adapting to TechnologyA theme 124 companies write about · 127 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2026: 28 of 57 companies on the "Worse" side.
1 other company's latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 124 companies compared. The sentences above are computed from all 124.Full recordFilings, disclosures and news, newest first
- FY2026AdvancedAnnual report
「In July 2026, we obtained manufacturing and marketing approval for the novel coronavirus (SARS-CoV-2)/influenza virus antigen test kit “ImmunoAce® SARS-CoV-2/Flu II,” among other products.」
As a response to risks relating to new product development and the maintenance of competitive advantages, the company identified obtaining manufacturing and marketing approval for a combination test kit as a specific development milestone. - FY2024First statedAnnual report
「Delays or interruptions in research and development could make it difficult to recover our R&D investment and affect performance over the long term. In addition, if our products lose their competitive advantage due to innovative technologies developed by other companies, product revenue could decline.」
Responses include coordination with sales, production, and quality departments, the adoption of external technologies, joint research with universities and medical institutions, and prioritization of development projects.